Protagonist Lands FDA Win, Threatens Immunology Giants
Protagonist’s First Approval Spells Trouble for Pharma’s Immunology Heavyweights
Protagonist Therapeutics will now sit back and collect cash from the J&J partnership, including an immediate $50 million payment.
Protagonist Therapeutics received its first FDA approval, securing a $50 million immediate payment from its Johnson & Johnson partnership. The breakthrough positions the biotech company to challenge established players in the immunology sector. Industry analysts suggest the approval could reshape competitive dynamics among major pharmaceutical immunology programs.
Explore More
Related News
Bondi struggled to prosecute Trump foes. But will a new attorney general make a difference?
Anchorage Daily News · 2026.04.05
German men aged 17-45 may need military approval for long stays abroad
BBC · 2026.04.05
Basketball Hall of Fame announces 2026 inductees
https://www.westernmassnews.com · 2026.04.05
Germany's Overlooked Exit Rule: Men Aged 17 to 45 Now Need Bundeswehr Permission to Leave - IMI Daily
IMI - Investment Migration Insider · 2026.04.05
Former Iowa State star Bridget Carleton taken first in WNBA expansion draft
KCCI · 2026.04.05
Virginia Announces Leadership Change for Women’s Basketball
Virginia Cavaliers Official Athletic Site · 2026.04.05